Traws Pharma, Inc. (TRAW) Stock Competitors & Peer Comparison

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, NVO has a market cap of 195B. Regarding current trading prices, TRAW is priced at $1.28, while NVO trades at $43.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas NVO's P/E ratio is 10.30. In terms of profitability, TRAW's ROE is +4.90%, compared to NVO's ROE of +0.66%. Regarding short-term risk, TRAW is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check NVO's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, VRTX has a market cap of 112.9B. Regarding current trading prices, TRAW is priced at $1.28, while VRTX trades at $444.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas VRTX's P/E ratio is 26.37. In terms of profitability, TRAW's ROE is +4.90%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, TRAW is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check VRTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TRAW is priced at $1.28, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TRAW's ROE is +4.90%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, TRAW is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check VRNA's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, REGN has a market cap of 63.1B. Regarding current trading prices, TRAW is priced at $1.28, while REGN trades at $612.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas REGN's P/E ratio is 14.94. In terms of profitability, TRAW's ROE is +4.90%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TRAW is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check REGN's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, TRAW is priced at $1.28, while ARGX trades at $893.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ARGX's P/E ratio is 39.71. In terms of profitability, TRAW's ROE is +4.90%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, TRAW is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ARGX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TRAW is priced at $1.28, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TRAW's ROE is +4.90%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TRAW is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check SGEN's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ALNY has a market cap of 37.8B. Regarding current trading prices, TRAW is priced at $1.28, while ALNY trades at $282.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ALNY's P/E ratio is 70.89. In terms of profitability, TRAW's ROE is +4.90%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, TRAW is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ALNY's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, RVMDW has a market cap of 36.1B. Regarding current trading prices, TRAW is priced at $1.28, while RVMDW trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas RVMDW's P/E ratio is N/A. In terms of profitability, TRAW's ROE is +4.90%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, TRAW is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check RVMDW's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, RVMD has a market cap of 32.7B. Regarding current trading prices, TRAW is priced at $1.28, while RVMD trades at $153.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas RVMD's P/E ratio is -21.64. In terms of profitability, TRAW's ROE is +4.90%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, TRAW is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RVMD's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, RPRX has a market cap of 23.6B. Regarding current trading prices, TRAW is priced at $1.28, while RPRX trades at $54.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas RPRX's P/E ratio is 28.88. In terms of profitability, TRAW's ROE is +4.90%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, TRAW is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RPRX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, TRAW is priced at $1.28, while UTHR trades at $545.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas UTHR's P/E ratio is 20.18. In terms of profitability, TRAW's ROE is +4.90%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, TRAW is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check UTHR's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, TRAW is priced at $1.28, while BNTX trades at $90.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas BNTX's P/E ratio is -15.50. In terms of profitability, TRAW's ROE is +4.90%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, TRAW is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BNTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, INCY has a market cap of 21.7B. Regarding current trading prices, TRAW is priced at $1.28, while INCY trades at $108.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas INCY's P/E ratio is 15.33. In terms of profitability, TRAW's ROE is +4.90%, compared to INCY's ROE of +0.29%. Regarding short-term risk, TRAW is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check INCY's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ROIV has a market cap of 21.6B. Regarding current trading prices, TRAW is priced at $1.28, while ROIV trades at $30.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ROIV's P/E ratio is -55.63. In terms of profitability, TRAW's ROE is +4.90%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, TRAW is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ROIV's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, INSM has a market cap of 21.2B. Regarding current trading prices, TRAW is priced at $1.28, while INSM trades at $97.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas INSM's P/E ratio is -16.99. In terms of profitability, TRAW's ROE is +4.90%, compared to INSM's ROE of -1.30%. Regarding short-term risk, TRAW is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check INSM's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TRAW is priced at $1.28, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TRAW's ROE is +4.90%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, TRAW is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BGNE's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, MRNA has a market cap of 19.8B. Regarding current trading prices, TRAW is priced at $1.28, while MRNA trades at $49.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas MRNA's P/E ratio is -6.13. In terms of profitability, TRAW's ROE is +4.90%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, TRAW is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MRNA's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TRAW is priced at $1.28, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TRAW's ROE is +4.90%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, TRAW is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check DNA-WT's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, NBIX has a market cap of 16.1B. Regarding current trading prices, TRAW is priced at $1.28, while NBIX trades at $159.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas NBIX's P/E ratio is 24.62. In terms of profitability, TRAW's ROE is +4.90%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, TRAW is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check NBIX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, GMAB has a market cap of 15.4B. Regarding current trading prices, TRAW is priced at $1.28, while GMAB trades at $25.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas GMAB's P/E ratio is 19.00. In terms of profitability, TRAW's ROE is +4.90%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, TRAW is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check GMAB's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, TRAW is priced at $1.28, while JAZZ trades at $230.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas JAZZ's P/E ratio is 2096.00. In terms of profitability, TRAW's ROE is +4.90%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, TRAW is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check JAZZ's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, TRAW is priced at $1.28, while ASND trades at $218.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ASND's P/E ratio is 25.01. In terms of profitability, TRAW's ROE is +4.90%, compared to ASND's ROE of -56.42%. Regarding short-term risk, TRAW is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ASND's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, EXEL has a market cap of 13.4B. Regarding current trading prices, TRAW is priced at $1.28, while EXEL trades at $53.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas EXEL's P/E ratio is 17.59. In terms of profitability, TRAW's ROE is +4.90%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, TRAW is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check EXEL's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, AXSM has a market cap of 13.1B. Regarding current trading prices, TRAW is priced at $1.28, while AXSM trades at $255.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas AXSM's P/E ratio is -68.59. In terms of profitability, TRAW's ROE is +4.90%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, TRAW is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check AXSM's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, TRAW is priced at $1.28, while BBIO trades at $66.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas BBIO's P/E ratio is -17.86. In terms of profitability, TRAW's ROE is +4.90%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, TRAW is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BBIO's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TRAW is priced at $1.28, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TRAW's ROE is +4.90%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TRAW is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check KRTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, IONS has a market cap of 12.1B. Regarding current trading prices, TRAW is priced at $1.28, while IONS trades at $73.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas IONS's P/E ratio is -36.46. In terms of profitability, TRAW's ROE is +4.90%, compared to IONS's ROE of -0.59%. Regarding short-term risk, TRAW is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check IONS's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TRAW is priced at $1.28, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TRAW's ROE is +4.90%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TRAW is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RNAM's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, TRAW is priced at $1.28, while MDGL trades at $480.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas MDGL's P/E ratio is -35.59. In terms of profitability, TRAW's ROE is +4.90%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, TRAW is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MDGL's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, SMMT has a market cap of 10.9B. Regarding current trading prices, TRAW is priced at $1.28, while SMMT trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas SMMT's P/E ratio is -8.81. In terms of profitability, TRAW's ROE is +4.90%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, TRAW is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check SMMT's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, TRAW is priced at $1.28, while BMRN trades at $55.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas BMRN's P/E ratio is 40.25. In terms of profitability, TRAW's ROE is +4.90%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, TRAW is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BMRN's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ARWR has a market cap of 10.5B. Regarding current trading prices, TRAW is priced at $1.28, while ARWR trades at $74.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ARWR's P/E ratio is -32.83. In terms of profitability, TRAW's ROE is +4.90%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, TRAW is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ARWR's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TRAW is priced at $1.28, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TRAW's ROE is +4.90%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TRAW is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RXDX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, KRYS has a market cap of 9.4B. Regarding current trading prices, TRAW is priced at $1.28, while KRYS trades at $317.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas KRYS's P/E ratio is 42.57. In terms of profitability, TRAW's ROE is +4.90%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TRAW is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check KRYS's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TRAW is priced at $1.28, while NUVL trades at $123.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas NUVL's P/E ratio is -20.34. In terms of profitability, TRAW's ROE is +4.90%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TRAW is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check NUVL's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CORT has a market cap of 8.9B. Regarding current trading prices, TRAW is priced at $1.28, while CORT trades at $82.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CORT's P/E ratio is 236.89. In terms of profitability, TRAW's ROE is +4.90%, compared to CORT's ROE of +0.08%. Regarding short-term risk, TRAW is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CORT's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CYTK has a market cap of 8.7B. Regarding current trading prices, TRAW is priced at $1.28, while CYTK trades at $70.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CYTK's P/E ratio is -10.24. In terms of profitability, TRAW's ROE is +4.90%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, TRAW is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CYTK's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TRAW is priced at $1.28, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TRAW's ROE is +4.90%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TRAW is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check IMGN's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, TRAW is priced at $1.28, while TECH trades at $54.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas TECH's P/E ratio is 77.14. In terms of profitability, TRAW's ROE is +4.90%, compared to TECH's ROE of +0.05%. Regarding short-term risk, TRAW is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check TECH's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TRAW is priced at $1.28, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TRAW's ROE is +4.90%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, TRAW is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BPMC's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, TRAW is priced at $1.28, while HALO trades at $69.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas HALO's P/E ratio is 24.39. In terms of profitability, TRAW's ROE is +4.90%, compared to HALO's ROE of +1.26%. Regarding short-term risk, TRAW is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check HALO's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TRAW is priced at $1.28, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CERE's P/E ratio is -16.47. In terms of profitability, TRAW's ROE is +4.90%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TRAW is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CERE's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, TGTX has a market cap of 7.6B. Regarding current trading prices, TRAW is priced at $1.28, while TGTX trades at $49.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas TGTX's P/E ratio is 17.31. In terms of profitability, TRAW's ROE is +4.90%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, TRAW is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check TGTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, IBRX has a market cap of 7.4B. Regarding current trading prices, TRAW is priced at $1.28, while IBRX trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas IBRX's P/E ratio is -8.35. In terms of profitability, TRAW's ROE is +4.90%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, TRAW is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check IBRX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TRAW is priced at $1.28, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TRAW's ROE is +4.90%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, TRAW is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MTSR's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ALKS has a market cap of 7.4B. Regarding current trading prices, TRAW is priced at $1.28, while ALKS trades at $44.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ALKS's P/E ratio is 49.20. In terms of profitability, TRAW's ROE is +4.90%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, TRAW is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ALKS's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, KYMR has a market cap of 7.1B. Regarding current trading prices, TRAW is priced at $1.28, while KYMR trades at $86.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas KYMR's P/E ratio is -24.08. In terms of profitability, TRAW's ROE is +4.90%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, TRAW is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check KYMR's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, PTGX has a market cap of 7.1B. Regarding current trading prices, TRAW is priced at $1.28, while PTGX trades at $109.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas PTGX's P/E ratio is -60.65. In terms of profitability, TRAW's ROE is +4.90%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, TRAW is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check PTGX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, TRAW is priced at $1.28, while IMVT trades at $33.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas IMVT's P/E ratio is -12.14. In terms of profitability, TRAW's ROE is +4.90%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, TRAW is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check IMVT's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, PCVX has a market cap of 6.9B. Regarding current trading prices, TRAW is priced at $1.28, while PCVX trades at $47.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas PCVX's P/E ratio is -6.89. In terms of profitability, TRAW's ROE is +4.90%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, TRAW is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check PCVX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TRAW is priced at $1.28, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TRAW's ROE is +4.90%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, TRAW is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MRUS's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TRAW is priced at $1.28, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TRAW's ROE is +4.90%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TRAW is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ACLX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, LEGN has a market cap of 6.6B. Regarding current trading prices, TRAW is priced at $1.28, while LEGN trades at $35.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas LEGN's P/E ratio is -25.99. In terms of profitability, TRAW's ROE is +4.90%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, TRAW is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check LEGN's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TRAW is priced at $1.28, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas RETA's P/E ratio is -66.29. In terms of profitability, TRAW's ROE is +4.90%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TRAW is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RETA's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, LQDA has a market cap of 6.3B. Regarding current trading prices, TRAW is priced at $1.28, while LQDA trades at $71.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas LQDA's P/E ratio is 419.00. In terms of profitability, TRAW's ROE is +4.90%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, TRAW is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check LQDA's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ABVX has a market cap of 6.3B. Regarding current trading prices, TRAW is priced at $1.28, while ABVX trades at $96.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ABVX's P/E ratio is -18.15. In terms of profitability, TRAW's ROE is +4.90%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, TRAW is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check ABVX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, PTCT has a market cap of 6.2B. Regarding current trading prices, TRAW is priced at $1.28, while PTCT trades at $75.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas PTCT's P/E ratio is -29.58. In terms of profitability, TRAW's ROE is +4.90%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, TRAW is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check PTCT's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, TRAW is priced at $1.28, while CNTA trades at $39.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CNTA's P/E ratio is -22.31. In terms of profitability, TRAW's ROE is +4.90%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TRAW is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CNTA's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, TRAW is priced at $1.28, while RYTM trades at $88.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas RYTM's P/E ratio is -28.24. In terms of profitability, TRAW's ROE is +4.90%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, TRAW is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RYTM's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, TRAW is priced at $1.28, while COGT trades at $33.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas COGT's P/E ratio is -15.25. In terms of profitability, TRAW's ROE is +4.90%, compared to COGT's ROE of -0.83%. Regarding short-term risk, TRAW is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check COGT's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, PRAX has a market cap of 5.6B. Regarding current trading prices, TRAW is priced at $1.28, while PRAX trades at $266.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas PRAX's P/E ratio is -19.92. In terms of profitability, TRAW's ROE is +4.90%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, TRAW is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check PRAX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TRAW is priced at $1.28, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TRAW's ROE is +4.90%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, TRAW is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CDTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, TRAW is priced at $1.28, while BLTE trades at $138.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas BLTE's P/E ratio is -54.39. In terms of profitability, TRAW's ROE is +4.90%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, TRAW is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BLTE's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TRAW is priced at $1.28, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TRAW's ROE is +4.90%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TRAW is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ABCM's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TRAW is priced at $1.28, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TRAW's ROE is +4.90%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TRAW is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ISEE's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, APGE has a market cap of 5.5B. Regarding current trading prices, TRAW is priced at $1.28, while APGE trades at $88.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas APGE's P/E ratio is -20.40. In terms of profitability, TRAW's ROE is +4.90%, compared to APGE's ROE of -0.33%. Regarding short-term risk, TRAW is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check APGE's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, TRAW is priced at $1.28, while FBIOX trades at $25.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas FBIOX's P/E ratio is N/A. In terms of profitability, TRAW's ROE is +4.90%, compared to FBIOX's ROE of N/A. Regarding short-term risk, TRAW is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check FBIOX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, TRAW is priced at $1.28, while SRRK trades at $44.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas SRRK's P/E ratio is -12.81. In terms of profitability, TRAW's ROE is +4.90%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, TRAW is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check SRRK's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, TRAW is priced at $1.28, while CGON trades at $59.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CGON's P/E ratio is -25.45. In terms of profitability, TRAW's ROE is +4.90%, compared to CGON's ROE of -0.23%. Regarding short-term risk, TRAW is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check CGON's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TRAW is priced at $1.28, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas APLS's P/E ratio is 38.35. In terms of profitability, TRAW's ROE is +4.90%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TRAW is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check APLS's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, LGND has a market cap of 5.1B. Regarding current trading prices, TRAW is priced at $1.28, while LGND trades at $255.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas LGND's P/E ratio is 33.36. In terms of profitability, TRAW's ROE is +4.90%, compared to LGND's ROE of +0.16%. Regarding short-term risk, TRAW is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check LGND's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, TRAW is priced at $1.28, while CAI trades at $17.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CAI's P/E ratio is -6.51. In terms of profitability, TRAW's ROE is +4.90%, compared to CAI's ROE of +0.06%. Regarding short-term risk, TRAW is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CAI's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, TRAW is priced at $1.28, while MIRM trades at $99.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas MIRM's P/E ratio is -7.30. In terms of profitability, TRAW's ROE is +4.90%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, TRAW is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MIRM's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, SYRE has a market cap of 4.9B. Regarding current trading prices, TRAW is priced at $1.28, while SYRE trades at $80.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas SYRE's P/E ratio is -38.11. In terms of profitability, TRAW's ROE is +4.90%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, TRAW is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check SYRE's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, TRAW is priced at $1.28, while TVTX trades at $52.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas TVTX's P/E ratio is -104.08. In terms of profitability, TRAW's ROE is +4.90%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, TRAW is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check TVTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, TRAW is priced at $1.28, while CRSP trades at $49.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CRSP's P/E ratio is -8.07. In terms of profitability, TRAW's ROE is +4.90%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, TRAW is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CRSP's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, TRAW is priced at $1.28, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas TERN's P/E ratio is -51.41. In terms of profitability, TRAW's ROE is +4.90%, compared to TERN's ROE of -0.20%. Regarding short-term risk, TRAW is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check TERN's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TRAW is priced at $1.28, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TRAW's ROE is +4.90%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TRAW is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check FOLD's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TRAW is priced at $1.28, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TRAW's ROE is +4.90%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, TRAW is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check AKRO's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TRAW is priced at $1.28, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TRAW's ROE is +4.90%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TRAW is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ALPN's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ERAS has a market cap of 4.4B. Regarding current trading prices, TRAW is priced at $1.28, while ERAS trades at $14.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ERAS's P/E ratio is -15.11. In terms of profitability, TRAW's ROE is +4.90%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, TRAW is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check ERAS's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, TRAW is priced at $1.28, while CELC trades at $88.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CELC's P/E ratio is -22.71. In terms of profitability, TRAW's ROE is +4.90%, compared to CELC's ROE of -2.45%. Regarding short-term risk, TRAW is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CELC's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TRAW is priced at $1.28, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas OPT's P/E ratio is -1.52. In terms of profitability, TRAW's ROE is +4.90%, compared to OPT's ROE of +1.09%. Regarding short-term risk, TRAW is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check OPT's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, TRAW is priced at $1.28, while XENE trades at $52.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas XENE's P/E ratio is -11.23. In terms of profitability, TRAW's ROE is +4.90%, compared to XENE's ROE of -0.49%. Regarding short-term risk, TRAW is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check XENE's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TRAW is priced at $1.28, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TRAW's ROE is +4.90%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TRAW is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MRTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, MANE has a market cap of 4B. Regarding current trading prices, TRAW is priced at $1.28, while MANE trades at $96.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas MANE's P/E ratio is -36.32. In terms of profitability, TRAW's ROE is +4.90%, compared to MANE's ROE of -0.95%. Regarding short-term risk, TRAW is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check MANE's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, KNSA has a market cap of 3.9B. Regarding current trading prices, TRAW is priced at $1.28, while KNSA trades at $51.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas KNSA's P/E ratio is 57.02. In terms of profitability, TRAW's ROE is +4.90%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, TRAW is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check KNSA's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, TRAW is priced at $1.28, while CPRX trades at $31.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CPRX's P/E ratio is 18.13. In terms of profitability, TRAW's ROE is +4.90%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TRAW is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CPRX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, TRAW is priced at $1.28, while VCYT trades at $47.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas VCYT's P/E ratio is 43.82. In terms of profitability, TRAW's ROE is +4.90%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, TRAW is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check VCYT's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TRAW is priced at $1.28, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TRAW's ROE is +4.90%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TRAW is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RYZB's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, TRAW is priced at $1.28, while EWTX trades at $34.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas EWTX's P/E ratio is -20.98. In terms of profitability, TRAW's ROE is +4.90%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, TRAW is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check EWTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TRAW is priced at $1.28, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TRAW's ROE is +4.90%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TRAW is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CBAY's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, TRAW is priced at $1.28, while CRNX trades at $34.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas CRNX's P/E ratio is -6.71. In terms of profitability, TRAW's ROE is +4.90%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TRAW is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check CRNX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, TRAW is priced at $1.28, while ACAD trades at $21.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas ACAD's P/E ratio is 9.81. In terms of profitability, TRAW's ROE is +4.90%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, TRAW is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ACAD's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, TRAW is priced at $1.28, while TNGX trades at $30.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas TNGX's P/E ratio is -37.28. In terms of profitability, TRAW's ROE is +4.90%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, TRAW is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check TNGX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, TRAW is priced at $1.28, while NAMS trades at $30.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas NAMS's P/E ratio is -17.08. In terms of profitability, TRAW's ROE is +4.90%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, TRAW is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check NAMS's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, TRAW is priced at $1.28, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas SWTX's P/E ratio is -13.78. In terms of profitability, TRAW's ROE is +4.90%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, TRAW is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check SWTX's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, DNLI has a market cap of 3.4B. Regarding current trading prices, TRAW is priced at $1.28, while DNLI trades at $21.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas DNLI's P/E ratio is -7.52. In terms of profitability, TRAW's ROE is +4.90%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, TRAW is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check DNLI's competition here

TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRAW stands at 11.7M. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, TRAW is priced at $1.28, while DNTH trades at $82.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRAW currently has a P/E ratio of -0.68, whereas DNTH's P/E ratio is -19.40. In terms of profitability, TRAW's ROE is +4.90%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, TRAW is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for TRAW.Check DNTH's competition here